Advertisement

Ginkgo biloba Extract EGb 761®: From an Ancient Asian Plant to a Modern European Herbal Medicinal Product

  • Friedrich Lang
  • Robert Hoerr
  • Michael Noeldner
  • Egon Koch
Chapter

Abstract

This chapter differs from the other chapters in the book in a number of aspects. First of all, it is not about traditional Chinese medicine (TCM) and hence does not describe internationally recognized standards which need to be established in the future to scientifically validate the traditional expertise on TCM. Rather, this chapter outlines the development process and present knowledge on EGb 761®, a special extract from leaves of Ginkgo biloba L. Although EGb 761® is produced from a plant which is native to China and other Asian countries; the extract was developed as a Western medicine.

Keywords

Traditional Chinese Medicine Ginkgo Extract Ginkgo Biloba Extract Herbal Medicinal Product Cerebral Energy Metabolism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abdel-Kader RM, Hauptmann S, Keil U, Scherping I, Leuner K, Eckert A, Mueller WE (2007) Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res 56(6):493–502Google Scholar
  2. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khatchaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B (2011) Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76:280–286Google Scholar
  3. Aldridge WN, Street BW, Skilleter DN (1977) Oxidative phosphorylation. Halide-dependent and halide-independent effects of triorganotin and trioganolead compounds on mitochondrial functions. Biochem J 168:353–64PubMedGoogle Scholar
  4. Arenz A, Klein M, Fiehe K, Gross J, Drewke C, Hemscheidt T, Leistner E (1996) Occurrence and biosynthesis of neurotoxic 4'-O-methylpyridoxine in Ginkgo biloba [Abstr. SL 20], 44th Annu. Congr. Med. Plant Res., Prague, CZ, 3.-7.9.1996, p 25Google Scholar
  5. Arenz A, Klein M, Fiehe K, Gross J, Drewke C, Hemscheidt T, Eckhard L (1996b) Occurrence of neurotoxic 4'-O-methylpyridoxine in Ginkgo biloba leaves, Ginkgo medications and Japanese Ginkgo food. Planta Med 62(6):548–551PubMedGoogle Scholar
  6. Auguet M, Clostre F, De Feudis FV (1986) Effects of antidepressants on receptor-activated and Ca2+-activated contractions of rabbit isolated aorta. Gen Pharmacol 17:607–610PubMedGoogle Scholar
  7. Augustin S, Rimbach G, Augustin K, Schliebs R, Wolffram S, Cermak R (2009) Effect of a short- and long-treatment with Ginkgo biloba extract on amyloid precursor protein levels in a transgenic mouse model relevant to Alzheimer’s disease. Arch Biochem Biophys 481:177–182PubMedGoogle Scholar
  8. Ahlemeyer B, Krieglstein J (2003) Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease. Pharmacopsychiatry 36(Suppl. 1): S8–S14PubMedGoogle Scholar
  9. Barkats M, Venault P, Christen Y, Cohen-Salmon C (1995) Effect of long-term treatment with EGb 761® on age-dependent structural changes in the hippocampi of three inbred mouse strains. Life Sci 56:213–222PubMedGoogle Scholar
  10. Barth SA, Inselmann G, Engemann R, Heidemann HT (1991) Influences of Ginkgo biloba on cyclosporin A induced lipid peroxidation in human liver microsomes comparison to vitamin E, glutathione and N-acetylcysteine. Biochem Pharmacol 41:1521–1526PubMedGoogle Scholar
  11. Bastianetto S, Ramassamy C, Doré S, Christen Y, Poirier J, Quirion R (2000) The Ginkgo biloba extract (EGb 761®) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 12:1882–90PubMedGoogle Scholar
  12. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J (2002) Natural history of mild cognitive impairment in older persons. Neurology 59:198–205PubMedGoogle Scholar
  13. Biber A, Koch E (1999) Bioavailability of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS. Planta Med 65:192–193PubMedGoogle Scholar
  14. Biber A (2003) Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry 36(Suppl. 1):S32–S37Google Scholar
  15. Blecharz-Klin K, Piechal A, Joniec I, Pyrzanowska J, Widy-Tyszkiewicz E (2009) Pharmacological and biochemical effects of Ginkgo biloba extract on learning, memory consolidation and motor activity in old rats. Acta Neurobiol Exp 69:217–231Google Scholar
  16. Blume J, Kieser M, Hölscher U (1996) Placebo-controlled double blind study on the efficacy of Ginkgo biloba special extract EGb 761® in maximum level trained patients with intermittent claudication (in German). Vasa 25:265–274PubMedGoogle Scholar
  17. Blumenthal M, Busse WR, Goldberg A, Gruenwald J, Hall T, Riggins CW, Rister RS, Klein S (1998) The complete German commission E monographs therapeutic guide to herbal medicines developed by a special expert Committee of the German Federal Institute for Drugs and Medical Devices. Am. Bot. Counc., Austin, TX, USAGoogle Scholar
  18. Boulie R, Munoz JF, Macovshi Panes O, Pacheco H (1988) Implication de la peroxidation lipidique dans l’intoxication par le triethyletain chez le rat. C R Seances Soc Biol Ses Fil 182:196–201Google Scholar
  19. Braquet P (1987) The ginkgolides: potent platelet-activating factor antagonists’ isolated from Ginkgo biloba L.: chemistry, pharmacology and clinical applications. Drugs Fut 12:643–699Google Scholar
  20. Bulling B, von Bary S (1991) The treatment of chronic peripheral arterial occlusion disease with physical exercise and Ginkgo biloba extract 761 (in German). Medwelt 42:702–708Google Scholar
  21. Chandrasekaran K, Mehrabian Z, Spinnewyn B, Chinopoulos C, Drieu K, Fiskum G (2002) Bilobalide, a component of the Ginkgo biloba extract (EGb 761®), protects against neuronal death in global brain ischemia and in glutamate-induced excitotoxicity. Cell Mol Biol 48:663–669PubMedGoogle Scholar
  22. Chatterjee SS (1985) Effect of Ginkgo biloba extract on cerebral metabolic processes. In: Agnoli A, Rapin JR, Scapagnini V, Weibrecht WV (eds) Effect of Ginkgo biloba extract on organic cerebral impairment. John Libbey Eurotext, London, pp 5–15Google Scholar
  23. Chatterjee SS, Gabard BL (1981) Protective effect of an extract of Ginkgo biloba and other hydroxyl radical scavengers against hypoxia [Abstr. 866]. IUPHAR 8th Int. Congr. Pharmacol. Tokyo, JP 19.7.1981–24.7.1981, p 483Google Scholar
  24. Chatterjee SS, Gabard BL (1982a) Studies on the mechanism of action of an extract of Ginkgo biloba, a drug used for treatment of ischemic vascular diseases [Abstr. 207]. Naunyn Schmiedeberg’s Arch Pharmacol 321(suppl):R52Google Scholar
  25. Chatterjee SS, Gabard BL (1982b) Protection of doxorubicin toxicity by an extract of Ginkgo biloba [Abstr. 57]. Naunyn Schmiedeberg’s Arch Pharmacol 319(suppl):R15Google Scholar
  26. Chatterjee SS, Gabard BL (1984) Effect of an extract of Ginkgo biloba on experimental neurotoxicities [Abstr. 327]. Naunyn Schmiedeberg’s Arch Pharmacol 325(suppl):R82Google Scholar
  27. Chatterjee SS, Noeldner M (1989) Behavioural observations demonstrating influences of the extract of Ginkgo biloba (EGb 761®) on some specific central cholinergic systems [Abstr. 425]. Naunyn Schmiedeberg’s Arch Pharmacol 339(suppl):R107Google Scholar
  28. Chatterjee SS, Cees J, Doelman A, Nöldner M, Biber A, Koch E (2005) Influence of the Ginkgo extract EGb 761® on rat liver cytochrome P450 and metabolism and excretion in rats and man. J Pharm Pharmacol 57:1–10Google Scholar
  29. Christen Y (2004) Ginkgo biloba and neurodegenerative disorders. Front Biosci 9:3091–3104PubMedGoogle Scholar
  30. Christen Y (2010) Does Ginkgo biloba extract exert an effect on Alzheimer’s disease progression? [ Chap. 17]. In: Micronutrients and brain health. Taylor & Francis, Boca Raton, FL, USA, Oxid Stress Dis 26:243–254
  31. Cohen-Salmon C, Venault P, Martin B, Raffalli-Sébille MJ, Barkats M, Clostre F, Pardon MC, Christen Y, Chapouthier G (1997) Effects of Ginkgo biloba extract (EGb 761®) on learning and possible actions on aging. J Physiol Paris 91:291–300PubMedGoogle Scholar
  32. Colciaghi F, Borroni B, Zimmermann M, Bellone C, Longhi A, Padovani A, Cattabeni F, Christen Y, Di Luca M (2004) Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis 16:454–460PubMedGoogle Scholar
  33. Continella G, Drago F (1984) Behavioral effect of Ginkgo biloba extract. In: Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV (eds) Effects of Ginkgo biloba-extract on organic cerebral impairment. John Libbey, London, pp 35–42Google Scholar
  34. De Feudis FV (2003) Ginkgo biloba extract, from chemistry to the clinic. Urban & Fischer, MunichGoogle Scholar
  35. De Kosky ST, Williamson J, Fitzpatrick A, Kronmal RA, Ives DG, Saxton J, Lopez O, Burke G, Carlson M, Fried L, Kuller LH, Robbins J, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD, for the GEM Study Investigators (2008) Ginkgo biloba for primary prevention of dementia: results of the Ginkgo evaluation of memory (GEM) study. JAMA 300:2253–2262Google Scholar
  36. De Marchi U, Campello S, Szabò I, Tombola F, Martinou JC, Zoratti M (2004) Bax does not directly participate in the Ca(2+)-induced permeability transition of isolated mitochondira. J Biol Chem 279:37415–22PubMedGoogle Scholar
  37. Dorman DC, Cote LM, Buck WB (1992) Effects of an extract of Ginkgo biloba on bromethalin-induced cerebral lipid peroxidation and edema in rats. Am J Vet Res 53:138–142PubMedGoogle Scholar
  38. Dumont E, Petit E, Tarrade T, Nouvelot A (1992) UV-C irradiation-induced peroxidative degradation of microsomal fatty acids and proteins: protection by an extract of Ginkgo biloba (EGb 761®). Free Radic Biol Med 13:197–203PubMedGoogle Scholar
  39. Eckert A, Keil U, Scherping I, Hauptmann S, Mueller WE (2005) Stabilization of mitochondrial membrane potential and improvement of neuronal energy metabolism by Ginkgo biloba extract EGb 761®. Ann N Y Acad Sci 1056:474–485PubMedGoogle Scholar
  40. EMEA/CHMP/SWP/431994 (2007) Guideline on the limits of genotoxic impuritiesGoogle Scholar
  41. Emerit I, Arutyunyan R, Oganesian N, Levy A, Cernjavsky L, Sarkisian T, Pogossian A, Asrian K (1995) Radiation-induced clastogenic factors: anticlastogenic effect of Ginkgo biloba extract. Free Radic Biol Med 18:985–991PubMedGoogle Scholar
  42. Erdinçler DS, Karakoç Y, Toplan S, Önen S, Sukyasyan A, Beğer T, Demiroğlu Ç (1996) The effect of Ginkgo biloba glycoside on the blood viscosity and erythrocyte deformability. Clin Hemorheol 16:271–276Google Scholar
  43. ESCOP (2003) Ginkgo biloba, Euro. Sci. Cooperative Phytother. (ESCOP). Thieme, StuttgartGoogle Scholar
  44. Fehske CJ, Leuner K, Müller WE (2009) Ginkgo biloba extract (EGb 761®) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacol Res 60:68–73PubMedGoogle Scholar
  45. Fitzl G, Welt K, Martin R, Dettmer D, Hermsdorf T, Clemens N, Konig S (2000) The influence of hypoxia on the myocardium of experimentally diabetic rats with and without protection by Ginkgo biloba extract. I. Ultrastructural and biochemical investigations on cardiomyocytes. Exp Toxicol Pathol 52:419–30PubMedGoogle Scholar
  46. Fourtillan JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K, Jouenne P, Biber A (1995) Proprietes pharmacocinetiques du Bilobalide et des Ginkgolides A et B chez le sujet sain apres administrations intraveneuses et orals d'extrait de Ginkgo biloba (EGb-761®) [Pharmacokinetics of bilobalide, Ginkgolide A and Ginkgolide B in healthy volunteers following oral and intravenous administrations of Ginkgo biloba extract (EGb 761®)]. Therapie 50(2):137–144PubMedGoogle Scholar
  47. Fransen HP (2010) Assessment of health claims, content, and safety of herbal supplements containing Ginkgo biloba. Food Nutr Res 54:5221Google Scholar
  48. Garcia-Alloza M, Dodwell SA, Meyer-Luehmann M, Hyman BT, Bacskai BJ (2006) Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model. J Neuropathol Exp Neurol 65:1082–9PubMedGoogle Scholar
  49. Gawron-Gzella A, Marek P, Chanay J, Matlawska I (2010) Comparative analysis of aharmaceuticals and dietary supplements containing extracts from the leaves of Ginkgo biloba L. Acta Pol Pharm 67(4):335–43PubMedGoogle Scholar
  50. Grass-Kapanke B, Busmane A, Lasmanis A, Hoerr R, Kaschel R (2011) Effects of Ginkgo biloba special extract EGb 761® in very mild cognitive impairment (vMCI). Neurosci Med 2:48–56Google Scholar
  51. Halama P, Bartsch G, Meng G (1988) Cerebrovascular insufficiency – placebo-controlled, randomised, doubleblind trial on the effect of Ginkgo biloba extract (in German). Fortschr Med 106:408–412PubMedGoogle Scholar
  52. Hamann KF (2007) Ginkgo special extract EGb 761® in vertigo: a systematic review of randomised, double-blind, placebo-controlled clinical trials. Internet J Otorhinolaryngol 6(2)Google Scholar
  53. Heiss WD, Zeiler K (1978) Medikamentöse Beeinflussung der Hirndurchblutung. Pharmakotherapie 1:137–144Google Scholar
  54. Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S, on behalf of the GOT-IT! Study Group (2012) Ginkgo biloba extract EGb 761(R) in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res 46:716–723Google Scholar
  55. Hofferberth B (1989) Effect of Ginkgo biloba extract on neurophysiological and psychometric measurement results in patients with cerebro-organic syndrome – a double-blind study versus placebo (in German). Arzneimittelforschung 39:918–922PubMedGoogle Scholar
  56. Hofferberth B (1991) Simultanerfassung elektrophysiologischer, psychometrischer und rheologischer Parameter bei Patienten mit hirnorganischem Psychosyndrom und erhöhtem Gefäßrisiko – Eine placebokontrollierte Doppelblindstudie mit Ginkgo-biloba-Extrakt EGb 761®. In: Stodtmeister R, Pillunat LE (eds) Mikrozirkulation in Gehirn und Sinnesorganen. Enke, Stuttgart, pp 64–74Google Scholar
  57. Horsch S, Walther C (2004) Ginkgo biloba special extract EGb 761® in the treatment of peripheral arterial occlusive disease (PAOD) – a review based on randomized, controlled studies. Int J Clin Pharmacol Ther 42:63–72PubMedGoogle Scholar
  58. Hoyer S, Lannert H, Noeldner M, Chatterjee SS (1999) Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761®). J Neural Transm 106:1171–1188PubMedGoogle Scholar
  59. Hsu CL, Wu YL, Tang GJ, Lee TS, Kou YR (2009) Ginkgo biloba extract confers protection from cigarette smoke extract-induced apoptosis in human lung endothelial cells: role of heme oxygenase-1. Pulm Pharmacol Ther 22:286–296PubMedGoogle Scholar
  60. Huang SH, Duke RK, Chebib M, Sasaki K, Wada K, Johnston GA (2003) Bilobalide, a sesquiterpene trilactone from Ginkgo biloba, is an antagonist at recombinant alpha1beta2gamma2L GABA(A) receptors. Eur J Pharmacol 464:1–8PubMedGoogle Scholar
  61. Huguet F, Tarrade T (1992) Alpha2-adrenoceptor changes during cerebral ageing: the effect of Ginkgo biloba extract. J Pharm Pharmacol 44:24–27PubMedGoogle Scholar
  62. Huguet F, Drieu K, Piriou A (1994) Decreased cerebral 5-HT1A receptors during ageing: reversal by Ginkgo biloba extract EGb 761®). J Pharm Pharmacol 46:316–318PubMedGoogle Scholar
  63. Ihl R, Bachinskaya N, Korczyn AD, Vakhapova V, Tribanek M, Hoerr R, Napryeyenko O, on behalf of the GOTADAY Study Group (2011) Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features – a randomized controlled trial. Int J Geriatr Psychiatry 26:1186–1194Google Scholar
  64. IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2008) Ginkgohaltige Präparate bei Alzheimer Demenz – Abschlussbericht A05–19B. IQWiG, KölnGoogle Scholar
  65. Israël L, Dell’Accio E, Martin G, Hugonot R (1987) Ginkgo biloba extract and memory training programs – comparative assessment on elderly outpatients living in the community (in French). Psychol Med (Paris) 19:1431–1439Google Scholar
  66. Ivic L, Sands TT, Fishkin N, Nakanishi K, Kriegstein AR, Strømgaard K (2003) Terpene trilactones from Ginkgo biloba are antagonists of cortical glycine and GABA(A) receptors. J Biol Chem 278:49279–85PubMedGoogle Scholar
  67. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9:119–128PubMedGoogle Scholar
  68. Jaggy H, Koch E (1997) Chemistry and biology of alkylphenols from Ginkgo biloba L. Pharmazie 52(10):735–738PubMedGoogle Scholar
  69. Janssens D, Michiels C, Delaive E, Eliaers F, Drieu K, Remacle J (1995) Protection of hypoxia-induced ATP decrease in endothelial cells by Ginkgo biloba extract and Bilobalide. Biochem Pharmacol 50:991–999PubMedGoogle Scholar
  70. Janssens D, Remacle J, Drieu K, Michiels C (1999) Protection of mitochondrial respiration activity by Bilobalide. Biochem Pharmacol 58:109–119PubMedGoogle Scholar
  71. Janssens D, Delaive E, Remacle J, Michiels C (2000) Protection by bilobalide of the ischaemia-induced alterations of the mitochondrial respiratory activity. Fundam Clin Pharmacol 14:193–201PubMedGoogle Scholar
  72. Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kölsch H, Luck T, Mösch E, van den Bussche H, Wagner M, Wollny A, Zimmermann T, Pentzek M, Riedel-Heller SG, Romberg HP, Weyerer S, Kaduszkiewicz H, Maier W, Bickel H, for the German Study on Aging, Cognition and Dementia in Primary Care Patients Study Group (2010) Prediction of dementia by subjective memory impairment. Arch Gen Psychiatry 67:414–422PubMedGoogle Scholar
  73. Kampkötter A, Pielarski T, Rohrig R, Timpel C, Chovolou Y, Wätjen W, Kahl R (2007) The Ginkgo biloba extract EGb 761® reduces stress sensitivity, ROS accumulation and expression of catalase and glutathione S-transferase 4 in Caenorhabditis elegans. Pharmacol Res 55:139–47PubMedGoogle Scholar
  74. Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R (1996) Proof of efficacy of the Ginkgo biloba special extract EGb 761® in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 29:47–56PubMedGoogle Scholar
  75. Karcher L, Zagrmann P, Krieglstein J (1984) Effect of an extract of Ginkgo biloba on rat brain energy metabolism in hypoxia. Naunyn-Schmiedeberg’s Arch Pharmacol 327:31–35Google Scholar
  76. Kaschel R, Hörr R, Kresimon J, Rychlik R (2007) Einfluss von Ginkgo-Spezialextrakt EGb 761® auf die Leistungsfähigkeit bei gesunden Probanden am Bildschirmarbeitsplatz – Offene klinische Studie im Prä-Post-Design mit Kontrollgruppe. Perfusion 16:3–9Google Scholar
  77. Kasper S, Schubert H (2009) Ginkgo biloba extract EGb 761® in the treatment of dementia: evidence of efficacy and tolerability (in German). Fortschr Neurol Psychiatr 77:494–506PubMedGoogle Scholar
  78. Keles MS, Demirci N, Yildirim A, Atamanalp SS, Altinkaynak K (2008) Protective effects of N-acetylcysteine and Ginkgo biloba extract on ischaemia-reperfusion-induced hepatic DNA damage in rats. Clin Exp Med 8:193–8PubMedGoogle Scholar
  79. Kellermann AJ, Kloft C (2011) Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy 31:490–502PubMedGoogle Scholar
  80. Klein J, Chatterjee SS, Loeffelholz K (1995) Hypoxia-induced release of choline from rat brain: potent inhibition by bilobalide. Biol Chem Hoppe-Seyler 376(suppl):S116Google Scholar
  81. Klein J, Chatterjee SS, Loeffelholz K (1997) Phospholipid breakdown and choline release under hypoxic conditions: inhibition by bilobalide, a constituent of Ginkgo biloba. Brain Res 755:347–350PubMedGoogle Scholar
  82. Klein J, Weichel O, Hilgert M, Rupp J, Chatterjee SS, Nawrath H (2003) Excitotoxic hippocampal membrane breakdown and its inhibition by bilobalide: role of chloride fluxes. Pharmacopsychiatry 36(suppl 1):78–83Google Scholar
  83. Koch E (2005) Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine 12:10–16PubMedGoogle Scholar
  84. Koch E, Chatterjee SS (1993) Experimentelle Grundlagen fuer die therapeutische Anwendung von Ginkgoextrakt EGb 761® bei der Behandlung vaskulaerer Erkrankungen. Haemostaseologie 13:11–27Google Scholar
  85. Koh PO (2009) Ginkgo biloba extract (EGb 761®) prevents increase of Bad-Bcl-X(L) interaction following cerebral ischemia. Am J Chin Med 37:867–876PubMedGoogle Scholar
  86. Koltermann A (2007) Influence of Ginkgo biloba extract EGb 761® on signaling pathways in endothelial cells. Dissertation, Pharm Biol Pharm, Ludwig-Maximilians-Universitaet, Muenchen DE. p 155Google Scholar
  87. Költringer P, Langsteger W, Eber O (1995) Dose-dependent hemorheological effects and microcirulatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761®. Clin Hemorheol 15:649–656Google Scholar
  88. Krieglstein J, Beck T, Seibert A (1986) Influence of an extract of Ginkgo biloba on cerebral blood flow and metabolism. Life Sci 39:2327–34PubMedGoogle Scholar
  89. Krieglstein J, Ausmeier F, El-Abhar H, Lippert K, Welsch M, Rupalla K, Henrich-Noack P (1995) Neuroprotective effects of Ginkgo biloba constituents. Eur J Pharm Sci 3:39–48Google Scholar
  90. Kristofikova Z, Benesova O, Tejkalova H (1992) Changes of high-affinity choline uptake in the hippocampus of old rats after long-term administration of two nootropic drugs (Tacrine and Ginkgo biloba extract). Dementia 3:304–307Google Scholar
  91. Krzywon M, Tawab M, Schubert-Zsilavecz M (2008) Ginkgohaltige Teeprodukte nicht ohne Risiko. Pharm Ztg 153(13):4474–4479Google Scholar
  92. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF, for the North American EGb Study Group (1997) A placebo-controlled, double-blind randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278:1327–1332PubMedGoogle Scholar
  93. Le Poncin-Lafitte M, Rapin J, Rapin JR (1980) Effects of Ginkgo Biloba on changes induced by quantitative cerebral microembolization in rats. Arch Int Pharmacodyn Ther 243:236–44PubMedGoogle Scholar
  94. Leistner E, Drewke C (2010a) Ginkgo biloba and ginkgotoxin. J Nat Prod 73:86–92PubMedGoogle Scholar
  95. Leistner E, Drewke C (2010b) Arznei- und Nahrungsmittel aus Ginkgo biloba Potenziell toxische Inhaltsstoffe und ihre Wirkmechanismen [Drug and nutrition aspects of Ginkgo biloba] Dtsch. Apoth Ztg 150(17):1930–1935Google Scholar
  96. Lin FY, Chen YH, Chen YL, Wu TC, Li CY, Chen JW, Lin SJ (2007) Ginkgo biloba extract inhibits endotoxin-induced human aortic smooth muscle cell proliferation via suppression of toll-like receptor 4 expression and NADPH oxidase activation. J Agric Food Chem 55:1977–1984PubMedGoogle Scholar
  97. Liu KX, Wu WK, He W, Liu CL (2007) Ginkgo biloba extract (EGb 761®) attenuates lung injury induced by intestinal ischemia/reperfusion in rats: roles of oxidative stress and nitric oxide. World J Gastroenterol 14:299–305Google Scholar
  98. Longpre F, Garneau P, Christen Y, Ramassamy C (2006) Protection by EGb 761® against beta-amyloid-induced neurotoxicity: involvement of NF-kappa B, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation. Free Radic Biol Med 41:1781–1794PubMedGoogle Scholar
  99. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, Khan I, Netzer WJ, Xu H, Butko P (2002) Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 99:12197–202PubMedGoogle Scholar
  100. Mahadevan S, Park Y (2008) Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. J Food Sci 73:R14–R19PubMedGoogle Scholar
  101. Martin R, Mozet C, Martin H, Welt K, Engel C, Fitzl G. (2010) Effect of Ginkgo biloba extract ( EGb 761® ) on parameters of oxidative stress in different regions of aging rat brain after acute hypoxia. Aging Clin. Exp. Res. [Epub ahead of print], DOI: 10.3275/7229Google Scholar
  102. Meier B, Hasler A, Sticher O (1992) HPLC analyses of the main Ginkgo acylflavonol glycosides. Planta Med 58(suppl 7):A688–A689Google Scholar
  103. Meyer B (1986) A mulitcentre, randomized, double-blind drug versus placebo study of Ginkgo biloba extract in the treatment of tinnitus (in French). Presse Med 15:1562–1564PubMedGoogle Scholar
  104. Mizuno M, Droy-Lefaix MT, Packer L (1996) Ginkgo biloba extract EGb 761® is a suppressor of AP-1 transcription factor stimulated by phorbol 12-myristate 13-acetate. Biochem Mol Biol Int 39:395–401PubMedGoogle Scholar
  105. Moeller CK, Kurt S, Scheich H, Schulze H (2009) Improvement of auditory discrimination learning by Ginkgo biloba extract EGb 761® (R). Neurosci Lett 463:219–222PubMedGoogle Scholar
  106. Moreau P (1975) Un nouveau stimulant circulatoire cérébral. Nouv Presse Med 4:2401–2402PubMedGoogle Scholar
  107. Moreau J-P, Bommelaer G, Buscail L, Benque A, Jacob CO, Galleyrand J, Ribet (1986) A preliminary results of a multicentric double blind trial of somatostatin [s] vs placebo [p] in akute pancreatitis [ap] [Abstr. 85], 8th Congr. Gastroenterol. (OMGE), 6th Congr. Dig. Endosc. (OMED), 3rd. Congr. Colo-Proctol., Sao Paolo BR, 7.-12.9.1986, Dig Dis Sci 31(10, Suppl.)Google Scholar
  108. Morgenstern C, Biermann E (1997) Ginkgo special extract (EGb 761®) in the treatment of tinnitus aurium – results of a randomized, double-blind, placebo-controlled study (in German). Fortschr Med Orig 115:7–11Google Scholar
  109. Morgenstern C, Biermann E (2002) The efficacy of Ginkgo special extract EGb 761® in patients with tinnitus. Int J Clin Pharmacol Ther 40:188–197PubMedGoogle Scholar
  110. Müller WE, Abdel-Kader RM, Fehske CJ, Leuner K (2009) Grundlagen der therapeutischen Anwendung von EGb 761® (R). Wirkung auf die Kraftwerke der Zellen. Pharm Unserer Zeit 38:408–416PubMedGoogle Scholar
  111. Mußgnug G, Alemany J (1968) Studies on disorders of peripheral arterial circulation. Part XV: problems of conservative therapy of obliterating disorders of peripheral circulation demonstrated on tincture and extract of Ginkgo biloba (in German). Arzneimittelforschung 18:453–550Google Scholar
  112. Myers S (2007) The complexities of botanical quality, natural products insider, http://www.naturalproductsinsider.com. Accessed 05 July 2011, Article not accessible)
  113. Napryeyenko O, Borzenko I, for the GINDEM-NP Study Group (2007) Ginkgo biloba special extract in dementia with neuropsychiatric features – a randomized, placebo-controlled, double-blind clinical trial. Arzneimittelforschung 57:4–11PubMedGoogle Scholar
  114. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357:169–175Google Scholar
  115. Niizuma K, Yoshioka H, Chen H, Kim GS, Jung JE, Katsu M, Okami N, Chan PH (2010) Mitochondrial and apoptotic neuronal death signaling pathways in cerebral ischemia. Biochim Biophys Acta 1802:92–9PubMedGoogle Scholar
  116. Noeldner M, Chatterjee SS (1994) Anxiolytic-like activity of bilobalide [Abstr. 388]. Naunyn Schmiedeberg’s Arch Pharmacol 349(suppl):R97Google Scholar
  117. Oberpichler-Schwenk H, Beck T, Abdel-Rahman MM, Bielenberg GW, Krieglstein J (1988) Effects of Ginkgo biloba constituents related to protection against brain damage caused by hypoxia. Pharmacol Res Commun 20:349–368Google Scholar
  118. Otani M, Chatterjee SS, Gabard BL, Kreutzberg GW (1986) Effect of an extract of Ginkgo biloba on Triethyltin-induced cerebral edema. Acta Neuropathol 69:54–65PubMedGoogle Scholar
  119. Pardon MC, Joubert C, Perez-Diaz F, Christen Y, Launay JM, Cohen-Salmon C (2000) In vivo regulation of cerebral monoamine oxidase activity in senescent controls and chronically stressed mice by long-term treatment with Ginkgo biloba extract (EGb 761®). Mech Ageing Dev 113:157–68PubMedGoogle Scholar
  120. Peter H, Fisel J, Weisser W (1966) Zur Pharmakologie der Wirkstoffe aus Ginkgo biloba. Arzneimittelforschung 16:719–25PubMedGoogle Scholar
  121. Pietta PG, Gardana C, Mauri PL, Maffei FR, Carini M (1995) Identification of flavonoid metabolites after oral administration to rats of a Ginkgo biloba extract. J Chromatogr B Biomed Appl 673(1):75–80PubMedGoogle Scholar
  122. Pincemail J, Deby C (1986) The antiradical properties of Ginkgo biloba extract. Presse Med 15(31):1475–1479PubMedGoogle Scholar
  123. Porsolt RD, Martin P, Lenegre A, Fromage S, Drieu K (1990) Effects of an extract of Ginkgo biloba (EGb 761® [TANAKAN]) on “learned helplessness” and other models of stress in rodents. Pharmacol Biochem Behav 36:963–971PubMedGoogle Scholar
  124. Rangel-Ordóñez L, Noeldner M, Schubert-Zsilavecz M, Wurglics M (2010) Plasma levels and distribution of flavonoids in rat brain after single and repeated doses of standardized Ginkgo biloba extract EGb 761® (R). Planta Med 76(15):1683–1690PubMedGoogle Scholar
  125. Rickard NS, Kowadlo N, Gibbs ME (2001) Effect of the Ginkgo biloba extract, EGb 761®, on memory formation in day-old chicks. Pharmacol Biochem Behav 69:351–358PubMedGoogle Scholar
  126. Rimbach G, Cermak R, Wolffram S (2004) Gene regulatory activity of Ginkgo biloba L. ( Chap. 5). In: Bao Y, Fenwick R (eds) Phytochemicals in health and disease. Marcel Dekker, New York, pp 105–119Google Scholar
  127. Rojas P, Rojas-Castañeda J, Vigueras RM, Rojas C (2000) Ginkgo biloba pretreatment partially protects from the dopaminergic neurotoxicity of 1-methyl-4-phenylpyridinium. Proc West Pharmacol Soc 43:87–8PubMedGoogle Scholar
  128. Rojas P, Garduño B, Rojas C, Vigueras RM, Rojas-Castañeda J, Rios C, Serrano-Garcia N (2001) EGb761 blocks MPP+-induced lipid peroxidation in mouse corpus striatum. Neurochem Res 26:1245–51PubMedGoogle Scholar
  129. Rojas P, Serrano-García N, Mares-Sámano JJ, Medina-Campos ON, Pedraza-Chaverri J, Ogren SO (2008) EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress. Eur J Neurosci 28:41–50PubMedGoogle Scholar
  130. Sakakibara H, Ishida K, Grundmann O, Nakajima JI, Seo S, Butterweck V, Minami Y, Saito S, Kawai Y, Nakaya Y, Terao J (2006) Antidepressant effect of extracts from Ginkgo biloba leaves in behavioral models. Biol Pharm Bull 29:1767–1770PubMedGoogle Scholar
  131. Saleem S, Zhuang H, Biswal S, Christen Y, Dore S (2008) Ginkgo Biloba extract neuroprotective action is dependent on heme oxygenase 1 in ischemic reperfusion brain injury. Stroke 39:3389–3396PubMedGoogle Scholar
  132. Sanceario G, Kreutzberg GW (1986) Stimulation of astrocytes affects cytotoxic brain edema. Acta Neuropathol 72:3–14Google Scholar
  133. Saponaro A, Gambelli G, Cosentino F (1971) First results from a clinical and instrumental investigation of the effects of a new phytotherapeutic substance on the cerebral and peripheral arterial circulation (in Italian). Minerva Med 62:4838–4849PubMedGoogle Scholar
  134. Schennen A (1988) Neue Inhaltsstoffe aus den Blaettern von Ginkgo biloba. l. sowie Praeparation 14c-markierter Ginkgo-flavonoidepharm Biol. Dissertation, Univ. MarburgGoogle Scholar
  135. Schindowski K, Leutner S, Kressmann S, Eckert A, Mueller WE (2001) Age-related increase of oxidative stress-induced apoptosis in mice: prevention by Ginkgo biloba extract (EGb 761®). J Neural Transm 108:969–978PubMedGoogle Scholar
  136. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M (2005) A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res 2:541–551PubMedGoogle Scholar
  137. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69:2197–2204PubMedGoogle Scholar
  138. Scholtyssek H, Damerau W, Wessel R, Schimke I (1997) Antioxidative activity of ginkgolides against superoxide in an aprotic environment. Chem Biol Interact 106:183–190PubMedGoogle Scholar
  139. Schötz K (2002) Detection of allergenic urushiols in Ginkgo biloba leaves. Pharmazie 57(7):508–510Google Scholar
  140. Shah ZA, Nada SE, Doré S (2011) Heme oxygenase 1, beneficial role in permanent ischemic stroke and in Gingko biloba (EGb 761®) neuroprotection. Neuroscience 180:248–255PubMedGoogle Scholar
  141. Shen J, Lee W, Gu Y, Tong Y, Fung PC, Tong L (2011) Ginkgo biloba extract EGb 761®) inhibits mitochondria-dependent caspase pathway and prevents apoptosis in hypoxia-reoxygenated cardiomyocytes. Chin Med 6:8PubMedGoogle Scholar
  142. Shi C, Wu F, Yew DT, Xu J, Zhu Y (2010) Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells. Apoptosis 15:715–727PubMedGoogle Scholar
  143. Smith JV, Burdick AJ, Golik P, Khan I, Wallace D, Luo Y (2002) Anti-apoptotic properties of Ginkgo biloba extract EGb 761® in differentiated PC12 cells. Cell Mol Biol 48:699–707PubMedGoogle Scholar
  144. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of Alzheimer disease – The Nun Study. JAMA 277:813–817PubMedGoogle Scholar
  145. Soulie C, Nicole A, Christen Y, Ceballos-Picot I (2002) The Ginkgo biloba extract EGb 761® increases viability of hnt human neurons in culture and affects the expression of genes implicated in the stress response. Cell Mol Biol 48:641–646PubMedGoogle Scholar
  146. Spiess E, Juretzek W (2004) Hagers Handbuch der Pharmazeutischen Praxis, CD-Ausg. Hager ROM, Springer, Berlin, Heidelberg Ginkgo biloba, HN 2032700Google Scholar
  147. Sram RJ, Binkova B (1993) Side-effects of psychotropic therapy. In: Packer L, Prilipko L, Christen Y (eds) Free radicals in the brain – aging, neurological and mental disorders; Joint Meeting World Health Organization (WHO), Found. IPSEN. Springer, Berlin, pp 153–166Google Scholar
  148. Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JF (2003) Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer’s disease by chronic Ginkgo biloba treatment. Exp Neurol 184:510–20PubMedGoogle Scholar
  149. Sticher O (1992) Ginkgo biloba – Analytik und Zubereitungsformen. Pharm Unserer Zeit 21(6):253–265PubMedGoogle Scholar
  150. Stoll S, Scheuer K, Pohl O, Mueller WE (1996) Ginkgo biloba extract (EGb-761) independently improves changes in passive avoidance learning and brain membrane fluidity in the aging mouse. Pharmacopsychiatry 29:144–149PubMedGoogle Scholar
  151. Su SY, Hsieh CL, Wu SL, Cheng WY, Li CC, Lo HY, Ho TY, Hsiang CY (2009) Transcriptomic analysis of EGb 761®-regulated neuroactive receptor pathway in vivo. J Ethnopharmacol 123:68–73PubMedGoogle Scholar
  152. Taillandier J, Ammar A, Rabourdin JP, Ribeyre JP, Pichon J, Niddam S, Pierart H (1986) Ginkgo biloba extract in the treatment of cerebral disorders due to ageing – a longitudinal, multicentric, double-blind, drug versus placebo trial (in French). Presse Med 15:1583–1587PubMedGoogle Scholar
  153. Tawab M, Krzywon M, Schubert-Zsilavecz M (2010) Nahrungsergänzungs-mittel mit Ginkgo unter der Lupe. Pharm Ztg 155(20):1994–1999Google Scholar
  154. Tchantchou F, Xu Y, Wu Y, Christen Y, Luo Y (2007) EGb 761® enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease. FASEB J 21:2400–2408PubMedGoogle Scholar
  155. Tendi EA, Bosetti F, Dasgupta SF, Stella AM, Drieu K, Rapoport SI (2002) Ginkgo biloba extracts EGb 761® and bilobalide increase NADH dehydrogenase mRNA level and mitochondrial respiratory control ratio in PC12 cells. Neurochem Res 27:319–323PubMedGoogle Scholar
  156. Ude C, Paulke A, Noeldner M, Schubert-Zsilavecz M, Wurglics M (2011) Plasma and brain levels of terpene trilactones in rats after an oral single dose of standardized Ginkgo biloba extract EGb 761® (R). Planta Med 77(3):259–264PubMedGoogle Scholar
  157. Upton R, (2003) Ginkgo leaf Ginkgo leaf dry extract Ginkog biloba L: standards of analysis, quality control and therapeutics. American Herbal Pharmacopoeia and Therapeutic Compendium, Santa Cruz, CA, USAGoogle Scholar
  158. Uríková A, Babusíková E, Dobrota D, Drgová A, Kaplán P, Tatarková Z, Lehotský J (2006) Impact of Ginkgo biloba Extract EGb 761® on ischemia/reperfusion-induced oxidative stress products formation in rat forebrain. Cell Mol Neurobiol 26:1343–53PubMedGoogle Scholar
  159. van Beek TA (ed) (2000) Ginkgo biloba. Harwood Academic Publishers, AmsterdamGoogle Scholar
  160. van Beek TA, Montoro P (2009) Chemical analysis and Quality control of Ginkgo biloba leaves, extracts and phytopharmaceuticals. J Chromatogr A 1216(11):2002–2032Google Scholar
  161. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S, for the GuidAge Study Group (2010) Results of GuidAge – a 5-year placebo-controlled study of the efficacy of EGb 761® 120 mg to prevent or delay Alzheimer’s dementia onset in elderly subjects with memory complaint. J Nutr Health Aging 14(suppl 2):S23Google Scholar
  162. Walesiuk A, Trofimiuk E, Braszko JJ (2005) Gingko biloba extract diminishes stress-induced memory deficits in rats. Pharmacol Rep 57:176–87PubMedGoogle Scholar
  163. Watanabe CMH, Wolffram S, Ader P, Rimbach G, Packer L, Maguire JJ, Schultz PG, Gohil K (2001) The in vivo neuromodulatory effects of the herbal medicine Ginkgo biloba. Proc Natl Acad Sci USA 98:6577–6580PubMedGoogle Scholar
  164. Wang BS, Wang H, Song YY, Qi H, Rong ZX, Wang BS, Zhang L, Chen HZ (2010) Effectiveness of standardized Ginkgo biloba extract on cognitive symptoms of dementia with a six-month treqatment: a bivariate random effect meta-analysis. Pharmacopsychiatry 43:86–91Google Scholar
  165. Weichel O, Hilgert M, Chatterjee SS, Lehr M, Klein J (1999) Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 360:609–15PubMedGoogle Scholar
  166. Weinmann S, Roll S, Schwarzbach C (2010) Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 10(14)Google Scholar
  167. Weitbrecht WU, Jansen W (1986) Ginkgo biloba extract in the treatment of primary degenerative dementia – placebo-controlled, double-blind and comparative study (in German). Fortschr Med 104:199–202PubMedGoogle Scholar
  168. Wesnes K, Simmons D, Rook M, Simpson P (1987) A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly. Hum Psychopharmacol 2:159–169Google Scholar
  169. Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA (2010) Neurodegenerative basis of age-related cognitive decline. Neurology 75:1070–1078PubMedGoogle Scholar
  170. Winter E (1991) Effects of an extract of Ginkgo biloba on learning and memory in mice. Pharmacol Biochem Behav 38:109–14PubMedGoogle Scholar
  171. Winter JC (1998) The effects of an extract of Ginkgo biloba, EGb 761®, on cognitive behavior and longevity in the rat. Physiol Behav 63:425–33PubMedGoogle Scholar
  172. Wirth S, Stemmelin J, Will B, Christen Y, Di Scala G (2000) Facilitative effects of EGb 761® on olfactory recognition in young and aged rats. Pharmacol Biochem Behav 65:321–6PubMedGoogle Scholar
  173. Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, Link CD, Luo Y (2006) Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761® and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26:13102–13113PubMedGoogle Scholar
  174. Yan FL, Zheng Y, Zhao FD (2008) Effects of Ginkgo biloba extract EGb-761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia. Acta Neuropathol 116:529–535PubMedGoogle Scholar
  175. Yeh YC, Liu TJ, Wang LC, Lee HW, Ting CT, Lee WL, Hung CJ, Wang KY, Lai HC, Lai HC (2009) A standardized extract of Ginkgo biloba suppresses doxorubicin-induced oxidative stress and p53-mediated mitochondrial apoptosis in rat testes. Br J Pharmacol 156:48–61PubMedGoogle Scholar
  176. Yoshitake T, Yoshitake S, Kehr J (2010) The Ginkgo biloba extract EGb 761® and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol 159:659–68PubMedGoogle Scholar
  177. Zhuang H, Pin S, Christen Y, Dore S (2002) Induction of heme oxygenase 1 by Ginkgo biloba in neuronal cultures and potential implications in ischemia. Cell Mol Biol 48:647–653PubMedGoogle Scholar
  178. Zou W, Kim BO, Zhou BY, Liu Y, Messing A, He JJ (2007) Protection against human immunodeficiency virus type 1 Tat neurotoxicity by Ginkgo biloba extract EGb 761® involving glial fibrillary acidic protein. Am J Pathol 171:1923–35PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  • Friedrich Lang
    • 1
  • Robert Hoerr
    • 1
  • Michael Noeldner
    • 1
  • Egon Koch
    • 1
  1. 1.Dr. Willmar Schwabe GmbH and Co. KGKarlsruheGermany

Personalised recommendations